EFFICACY AND SAFETY OF HERBAL MEDICINE BOJUNGIKKI-TANG IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB MONOTHERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER: STUDY PROTOCOL FOR A RANDOMIZED, OPEN-LABEL, DOUBLE-ARM, MULTICENTER TRIAL

Efficacy and Safety of Herbal Medicine Bojungikki-Tang in Combination with Pembrolizumab versus Pembrolizumab Monotherapy for Stage IV Non-Small Cell Lung Cancer: Study Protocol for a Randomized, Open-Label, Double-Arm, Multicenter Trial

Background: Non-small cell lung cancer (NSCLC) exhibits low survival rates.Although immune checkpoint inhibitors (ICIs) have become first-line treatment for NSCLC, their limited response to ICI monotherapy has led to exploration of combination treatments.However, the high incidence of treatment-related adverse events associated with conventional dr

read more